Metástasis orales y maxilares: análisis clínico retrospectivo de 21 casos by Prol, Carlos et al.
Rev Esp Cir Oral Maxilofac. 2019;41(3):99-108
Original
Oral and maxillary metastases:  
retrospective clinical analysis of 21 cases
*Corresponding author:
E-mail address: drprolteijeiro@gmail.com (Carlos Prol Teijeiro).
DOI: 10.20986/recom.2019.1058/2019
A B S T R A C T
Objective: Retrospective descriptive study of 21 oral soft tissue and/or maxillary bone meta-
static cases.
Materials and methods: Hospital records of our own department are reviewed for a 12-year 
period. Lymphoproliferative diseases, skin metastases, salivary glands, other craniofacial 
bones and cervical lymph-nodes are excluded. Epidemiologic, personal health, clinical, treat-
ment and follow-up data are recollected and analysed in frequency statistics. 
Results: Male:Female ratio is 1.3:1, year-old range 52-82 and ethnic group 100 % white-cauca-
sian. 19.0 % have carcinogenic occupational exposure, 52.4 % tobacco abuse, 61.9 % some kind 
of alcohol use, 57.1 % cardiovascular risk, 19.0 % cardiologic records, 28.6 % pulmonary, 19.0 % 
gastrointestinal, 19.0 % endocrine, 14.3 % genitourinary, 9.5 % other primary malignancy 
and 23.8% a first-degree relative with a neoplasm. 33.3 % patients have taken osteonecrosis-
related drugs or received craniofacial radiotherapy. 
Metastasis is the debut in 7 patients while it corresponds to infirmity progression in 14. The 
chief reason for consultation is a mass. 8 lesions affect soft tissue and 13 the bone. 81.0 % 
have epithelial neoplasm lineages. The organ of origin is: 23.8 % lung, 23.8 breast, 23.8 % kid-
ney, 9.5 % skin, 9.5 % soft parts, 4.8 % prostate and 4.8 % thyroid. 100 % have other location 
metastases. 14.3 % patients undergo surgery, 38.1 % receive radiotherapy, 47.6 % chemo- or 
targeted therapy, and 28.6 % symptomatic treatment. After a 1-124 months range of follow-
up, 17 patients die and 4 are alive.
1130-0558/© 2019 SECOM. Publicado por Inspira Network. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://
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INTRODUCTION
Less than 3 % of malignant oral and maxillary lesions are 
metastases. Primary infraclavicular solid tumours that most 
commonly spread to head & neck are from epithelial strain 
and lung or breast origin. Most frequently affected regions 
are the attached gingiva in regard to oral soft tissues, and the 
mandible in the molar area in regard to bones. Typical reasons 
for consultation are an exophytic nodule or mass, with bleed-
ing tendency, inflammation, pain or sensory disturbance1,2.
MATERIAL AND METHODS
Our work centre is a tertiary level hospital, which covers 
about a 385.000 population area in relation to Oral & Maxillofa-
cial public assistance. Every patient with a malignant tumour 
diagnosis in our department is included in a clinical session of 
our own and a multidisciplinary one. A complete review of the 
session records is performed, from January 2003 to December 
2018. This study is retrospective of a standard diagnosis and 
treatment praxis, so institutional review board approval was 
exempt. 21 cases of metastatic lesions located in soft tissue of 
the mouth and/or maxillary bones are found. Excluding crite-
ria are: less than 18-year-old; metastases located in the skin, 
salivary glands, other craniofacial bones and exclusive cervical 
lymph-node affectation; lymphoproliferative disorders; and 
not-known origin. 
Epidemiologic data, general potentially carcinogenic and 
personal health records (PHR), first-degree relative oncologic 
processes, current disease, neoplasm strain and origin, treat-
ment and follow-up data are collected. 
In relation to toxic habits, tobacco abuse is considered in 
three levels: less or equal than 5 pack-years (+), between more 
than 5 and less or equal than 15 pack-years (++), and more 
than 15 pack-years (+++). In similar way, alcohol use is codi-
fied in other three levels: less or equal than 2 alcohol units/
day (+), between more than 2 and less or equal than 8 units/
day (++), and more than 9 units/day (+++).  In relation to PHR, 
usual cardiovascular risk factors are considered (hyperten-
sion, type 2 diabetes, hyperlipidemia). Cardiologic records 
include arrhythmias, ischemic heart disease, valvulopathies 
and other miocardiopathies. Pulmonary records cover chron-
ic obstructive pulmonary disease, asthma, obstructive sleep 
apnoea, lung infection sequels (basically tuberculosis) and 
other fibrous lung disorders. Gastrointestinal records include 
Conclusions: Craniomaxillofacial metastases, usually with multiple visceral or axial skeleton 
lesions, have an ominous prognosis. Multidisciplinary management could benefit the patient 
status and lead to more favourable outcomes. There are exceptional cases of long-term survival.
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R E S U M E N
Objetivo: Estudio descriptivo retrospectivo de 21 casos de metástasis en tejidos blandos orales 
y/o huesos maxilares.
Material y métodos: Revisión a 12 años de actas de nuestro departamento, excluyendo procesos 
linfoproliferativos, metástasis cutáneas, glándulas salivales, otros huesos craneofaciales y 
ganglios cervicales. Se recopilan datos epidemiológicos, antecedentes, clínicos, tratamiento 
y seguimiento, y analizan mediante estadísticos de frecuencia.
Resultados: La proporción varón:mujer es 1,3:1, entre 52-82 años y todos de etnia blanco-
caucásica. El 19,0 % tiene exposición laboral carcinógena, el 52,4 % tabaquismo, el 61,9 % 
consumo de alcohol, el 57,1 % riesgo cardiovascular, el 19,0 % patología cardiaca, el 28,6 % 
pulmonar, el 19 % gastrointestinal, el 19 % endocrina, el 14,3 % genitourinaria, el 9,5 % otro 
tumor maligno primario y el 23,8 % un familiar de primer grado con una neoplasia, el 33,3 % 
ha tomado fármacos asociados a osteonecrosis o recibido radioterapia craneofacial. 
Siete pacientes debutan con la metástasis y 14 como progresión de neoplasia conocida. El 
motivo de consulta principal es una masa. Ocho lesiones afectan a tejidos blandos y 13 al 
hueso. El 81 % son tumores de estirpe epitelial. El origen es: 23,8 % pulmón, 23,8 % mama, 
23,8 % renal, 9,5 % piel, 9,5 % partes blandas, 4,8 % próstata y 4,8 % tiroides. El 100 % tiene 
metástasis en otras localizaciones. El 14,3% pacientes son tratados con cirugía, el 38,1 % con 
radioterapia, el 47,6 % con quimio- o terapia dirigida, y el 28,6 % con tratamiento sintomático. 
17 pacientes fallecidos y 4 vivos con rango 1-124 meses de seguimiento. 
Conclusiones: Las metástasis craneomaxilofaciales, habitualmente con múltiples lesiones vis-
cerales o en esqueleto axial, tienen pronóstico infausto. El manejo multidisciplinar podría 
beneficiar el estado basal del paciente y llevar a mejores resultados.  Existen casos excepcio-
nales de supervivencia a largo plazo.
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DISCUSSION
 
Metastasis is the main cause of morbidity and mortality in 
most oncologic patients. Almost any malignant tumour could 
disseminate to the head and neck. Most common primary sites 
differ between genders and geographic area, mainly between 
Eastern and Western series. This fact may reflect differences 
in the prevalence of primary tumours and indirectly onco-
logic risk factors, genetics and lifestyles. Most reported cases 
in the literature are from United States of America, inserting 
an important geographic bias5,6.
A literature review of recent similar single/double institu-
tion case-series as ours is performed, with more than 15 cases 
and a 10-year period minimum (Table III)5,7-19. Inclusion and 
exclusion criteria are very heterogeneous. Two series only focus 
in one region7,15. Several of them consider other maxillofacial 
regions for metastasis target, such as the parotid gland, head 
& neck skin and cervical lymph-nodes, apart from oral soft 
tissues and jaws. We reported metastases from solid tumours 
including melanocytic origin, while other studies include 
lymphoproliferative disorders and not-known primary cancer 
localization neither histology.  Men are more prevalent than 
women in all the series except one from Brazil14. Mean age is 
between the 5th and 7th decades, but oral metastases could 
develop at any age. Some studies consider for their analysis 
children versus adults, because of radically different lineage, 
origin and better prognosis in the first ones17. Most common 
tissue lineage of solid tumours is epithelial, carcinomas or and 
adenocarcinomas, in all the series. Regarding the metastasis 
source, it is lung or breast in Western countries while it stands 
out lung or liver in the Eastern ones. Except ours and other one 
from France15, mean survival of solid tumours is equal or less 
than 16 months in all the series. One of the main differences 
of our study from all the others is the inclusion of detailed 
background of the patients.
Tumour cells have unique heterogeneous and plasticity 
properties due to innate and acquired accumulated muta-
tions. Before a metastatic lesion is established, sequential 
steps happen, known as the invasion-metastasis cascade. They 
are: penetration through the extracellular matrix (ECM) from 
the primary tumour, intravasation into the vessels, circulation 
until settlement in the microvasculature target organ, extrava-
sation, invasion of the underlying EMC, and angiogenesis 
processes. Highly perfused organs, such as the lung capillary 
network, are usual locations where circulating tumour cells 
could be passively trapped. Inflammatory microenviroment 
could help to engraft and proliferate. Bone marrow with its 
stromal cells, chemokines, integrins and other pro-growing 
molecules, is also a favourable target for metastasis. Bone 
remodelling, by OPG/RANK/RANKL pathways and by osteo-
clasts and osteoblasts cells, is corrupted, developing a mix of 
osteolytic, usually predominant, and osteoblastic elements in 
metastatic lesions1,2,7,20.
Many cases of soft tissues and bone craniomaxillofacial 
metastasis happen in patients with widespread disease, 
probably result of secondary spread from other metastasis, 
especially located in the lungs. Other proposed theories, espe-
cially in cases where the head & neck metastases is the first 
indication of occult malignancy, are that circulating tumour 
oesophageal reflux disease, peptic ulcer, diverticles, benign 
adenomas, and infectious, alcoholic or autoimmune hepatic 
diseases. Endocrine records cover goitre and other thyroid 
affections, osteoporosis and other metabolic bone conditions. 
Genitourinary records include hyperuricemia, chronic renal 
failure and other nephropathies, endometriosis and ovary 
cysts. Even other general background data could be collected, 
it was not considered for the present study to not overburden 
it with irrelevant information. 
Furthermore, any treatment which involves osteonecrosis 
as an adverse effect was specifically collected.
A retrospective descriptive analysis of frequencies is carried 
out with the Microsoft Excel® 2007 software.
RESULTS
There are 17 unreported cases while case number 11, 
12, 13 and 20 have been published before as case-reports3,4. 
12 patients are males and 9 females, with mean age of 62.9 
years-old, 52-82 range. All of them are white-caucasians. In 
relation to PHR, 19.0 % of the patients have a potentially car-
cinogenic occupational exposure, every one of them from lung 
origin. 52.4 % refer some kind of tobacco abuse, 61.9 % alcohol 
use and no one other substance abuse. 9.5 % have some drug-
related allergy reported. One or more cardiovascular risk factor 
are known in 57.1 %, cardiologic records in 19.0 %, pulmonary 
in 28.6 %, gastrointestinal in 19.0 %, endocrine in 19.0 % and 
genitourinary in 14.3 %. 9.5 % suffered other malignant tumour 
different from the current one, and 23.8 % have a first-degree 
relative with a neoplasm. 33.3 % patients, due to oncologic 
process, have received treatment with bisphosphonates or 
other osteonecrosis-related drugs, or received craniofacial 
radiotherapy (Table I). 
The metastasis is the malignancy debut in 7 patients. It cor-
responds to infirmity progression in 14, only 2 of them with-
out previous stage IV, with range of 1-252 months from the 
first oncologic diagnosis. The reason of consultation is a mass 
in 66.7 %, nodule 14.2 %, temporo-mandibular joint dysfunc-
tion 4.8 % and scheduled examination finding (periostitis in 
computed tomography and high uptake in scintigraphy) 9.5 %. 
Localization is soft tissue in 8 patients and the maxilla, the 
mandible or both in 13 (Figure 1). 81.0 % neoplasms are from 
epithelial lineage, 9.5 % melanoma and 9.5 % sarcoma. 23.8 % 
of the tumours originated in the lung, 23.8 % breast, 23.8 % kid-
ney, 9.5 % skin, 9.5 % soft parts, 4.8 % prostate and 4.8 thyroid 
(Figure 2). Oncogene studies, available in 4 patients, reveal 2 
ERRB2 positive cases, both of them from breast origin. All of 
the patients have at some point of the evolution metastases 
in other localizations, highlighting bones (66.7 %) and lungs 
(56.3 %), excluding the primary ones of these regions (Table II). 
The maxillofacial metastasis treatment is surgery in 14.3 %, 
radiotherapy 38.1 %, chemo-/immune-/biological therapy in 
47.6 % and just symptomatic treatment in 28.6 %, which coin-
cides with those patients who die before less than 5 months 
after the metastasis diagnosis. Follow-up ranges from 1 to 124 
months. 17 patients die, 2 of the living have stable infirmity, 1 
is in progression and 1 has no evidence of disease. Taking in 
account those patients who still are alive, the main survival 
is 23.0 months (Table II).
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Figure 2. Primary neoplasm origin, global and stratified  
by sex.
cells bypass the lung circulation through the valveless verte-
bral venous plexux. Furthermore, because of the tumour cells 
plasticity, they could spread through arteriovenous shunts1,3.
Jawbones are slightly more common affected than soft-
tissues. The mandible in molar area, premolar and the angle/
ramus are the most frequent localizations. Pathogenesis is 
not clear, but there are a haematopoietic marrow remainder 
located in the posterior part of the mandible in adults1,4. In 
relation to soft tissues, the attached gingiva and tongue are 
common affected sites, considering the chronic inflammation 
a co-factor in the attraction of metastatic cells1,20. 
Main clinical differential diagnosis of metastatic lesions is 
with primary oral squamous cell carcinoma, benign tumours 
and reactive lesions such as pyogenic granuloma or gigantic 
epulis. They typically present as big masses with local inflam-
mation which could infiltrate, even ulcerate skin; and they 
have bleeding tendency, especially of renal and hepatic origin. 
Occasionally, symptoms are a bit confusing such us TMJ dys-
function or numbness, known as numb chin syndrome, and 
the diagnosis is delayed because of deviated attention to minor 
stomatognathic processes. Incidental finding of asymptomatic 
lesions in scheduled x-ray explorations is a possibility too1,3,16,21.
Histological malignancy morphology is not definitive of 
metastasis, especially complex in low differentiated salivary 
gland tumours. The basic inmunohistochemical (IHC) panel 
usually include carcinoma (keratins, p53), melanoma (S-100), 
sarcoma (vimentin) and lymphoma (CD45) markers (Figure 3). 
Even with additional IHC and molecular techniques to dis-
cern the origin, sometimes the primary site remains obscure1. 
Intraoral located malignant melanoma lesions are sometimes 
very troublesome to discern the primary site, which could even 
present spontaneous regression22. 
The typical radiological appearance of metastatic lesions is 
a huge infiltrating, and destructive lesion, with poorly defined 
margins, central necrosis, and contrast enhancement (Figure 4). 
However, no pathognomonic image exists and any possibil-
ity is available. Bone lesion patrons tend to be osteolytic but 
also small osteoblastic areas could be appreciated in most of 
them6,23. It could be difficult to differentiate from osteonecrosis, 
inasmuch as a lot of patients have radiotherapy or associated 
drugs uptake (biphosphonates, RANKL inhibitors, VEGF inhibi-
tors) background. This situation is more troublesome in cases 






















without soft tissue mass. Given high suspicion and repeatedly 
negative biopsies, or region of difficult access such as TMJ, posi-
tron emission topographies could help to discern in favour of 
metastasis, as long as osteonecrosis is not in the active infection 
phase (Figure 5). In addition, the evolution and non-response to 
osteonecrosis treatment protocols will define the situation24,25. 
Management of head & neck metastatic tumours should 
be multidisciplinary and individualized to each patient. Main 
parameters of therapy are general health condition, type and 
localization of the primary tumour and metastasis. Surgery, 
radiotherapy and systemic treatment are possible, being the 
palliative care the need of the hour result of the poor overall 
prognosis. Average survival rate in craniomaxillofacial dis-
semination is less than 1 year in most large case-series1,2,6,8.








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3. Case 2. Lung adenocarcinoma metastasis. Fibrous connective 
tissue extensively infi ltrated by atypical cell solid nests. Pallid eosinophilic 
and slightly vacuolated cytoplasm, irregular nuclei with vesiculated 
chromatin and prominent nucleoli. A) 200x Hematoxilin & Eosin. B) 400x 
CK7+. C) 400x TTF-1+.
Figure 4. Case 21. Thyroid follicular carcinoma metastasis. Solid litic 
expansive lesion involving the right mandible ramus and condyle. A) 
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CONCLUSIONS
Craniomaxillofacial metastases are usually late complications 
of advanced neoplasm with multiple visceral or axial skeleton 
lesions. In some occasions they could be the tumour debut. Most 
common localizations are in the mandible body and attached 
gingival. Most frequent strain of solid tumours is epithelial, and 
origin is lung, breast or liver in recent series, slightly variable 
depending on the geographical source and sex stratification. 
Multidisciplinary management could benefit the patient status 
and lead to more favourable outcomes, in terms of quality of life 
and function. There are exceptional cases of long-term survival.
ACKNOWLEDGEMENTS
To every member of the Head & Neck Tumours committee 
of the Cruces University Hospital.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
Preliminary results were presented in the “Congreso de 
Cirugía Oral e Implatología 17ed, Ibiza 2018” in Oral Comuni-
cation format: Lesiones metastásicas orales y maxilares (C. Prol, 
S. Ruiz-Oslé, S. Malaxetxebarria, A. Dolado, O. M. del Hoyo, L. 
Barbier).
SCHOLARSHIP/FINANCIAL AID
Neither scholarship nor financial aid were received.
R E F E R E N C E S
1. Hirshberg A, Berger R, Allon I, Kaplan I. Metastatic tumors to 
the jaws and mouth. Head Neck Pathol. 2014;8(4):463-74. DOI: 
10.1007/s12105-014-0591-z.
Figure 5. Case 14. Renal cromophobe carcinoma metastases. A-C) Fluordeoxiglucose-18 positron emission tomography. Rigth 
mandibule ramus periosteum inflammation, especially pronounced in the vestibular cortical, with high uptake (6.6 SUVmax). 
D) Computed tomography 9 months later. Progression to a mixed osteolitic and osteoblastic lesion.
A B C D
2. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Met-
astatic tumours to the oral cavity - pathogenesis and analysis 
of 673 cases. Oral Oncol. 2008;44(8):743-52. DOI: 10.1016/j.ora-
loncology.2007.09.012.
3. Ruiz-Osle S, Prol C, Lardies R, Gaafar A, Barbier L, Arruza A. 
Renal Cell Carcinoma metastases in the maxillofacial area: 
Case series. Arch Esp Urol. 2017;70(8):732-5.
4. Prol C, Ruiz-Osle S, Malaxetxebarria S, Álvarez J. Metastatic 
prostate adeno-carcinoma and Paget’s bone disease of the 
mandible. Rev Osteoporos Metab Miner. 2018;10(1):37-40. DOI: 
10.4321/S1889-836X2018000100006.
5. Shen M-L, Kang J, Wen Y-L, Ying W-M, Yi J, Hua C-G, et al. Met-
astatic Tumors to the Oral and Maxillofacial Region: A Retro-
spective Study of 19 Cases in West China and Review of the 
Chinese and English Literature. J Oral Maxillofac Surg. 
2009;67(4):718-37. DOI: 10.1016/j.joms.2008.06.032.
6. Irani S. Metastasis to the Jawbones: A review of 453 cases. J Int 
Soc Prev Community Dent. 2017;7(2):71-81. DOI: 10.4103/jispcd.
JISPCD_512_16. 
7. D’Silva NJ, Summerlin DJ, Cordell KG, Abdelsayed RA, Tomich 
CE, Hanks CT, et al. Metastatic tumors in the jaws: a retrospec-
tive study of 114 cases. J Am Dent Assoc. 2006;137(12):1667-72. 
DOI: 10.14219/jada.archive.2006.0112.
8. Friedrich RE, Abadi M. Distant Metastases and Malignant Cel-
lular Neoplasms Encountered in the Oral and Maxillofacial 
Region: Analysis of 92 Patients Treated at a Single Institution. 
Anticancer Res. 2010;30(5):1843-8.
9. Thiele OC, Freier K, Bacon C, Flechtenmacher C, Scherfler S, 
Seeberger R. Craniofacial metastases: A 20-year survey. J Cra-
niomaxillofac Surg. 2011;39(2):135-7. DOI: 10.1016/j.
jcms.2010.10.009. 
10. Daley T, Darling MR. Metastases to the Mouth and Jaws: A 
Contemporary Canadian Experience. J Can Dent Assoc. 
2011;77.b67.
11. Jham BC, Salama AR, McClure SA, Ord RA. Metastatic tumors 
to the oral cavity: a clinical study of 18 cases. Head Neck 
Pathol. 2011;5(4):355-8. DOI: 10.1007/s12105-011-0286-7. 
12. Shin SJ, Roh JL, Choi SH, Nam SY, Kim SY, Kim SB, et al. Meta-
static Carcinomas to the Oral Cavity and Oropharynx. Korean 
J  Pathol. 2012;46(3) :266-71. DOI:  10.4132/KoreanJ-
Pathol.2012.46.3.266. 
13. McClure SA, Movahed R, Salama A, Ord RA. Maxillofacial Me-
tastases: A Retrospective Review of One Institution’s 15-Year 
Experience. J Oral Maxillofac Surg. 2013;71(1):178-88.  DOI: 
10.1016/j.joms.2012.04.009. 
14. Servato JP, de Paulo LFB, de Feria PR, Cardoso SV, Loyola AM. 
Metastatic tumours to the head and neck: retrospective anal-
108 REV ESP CIR ORAL MAXILOFAC. 2019;41(3):99-108
ysis from a Brazilian tertiary referral centre. Int J Oral Maxil-
lofac Surg. 2013;42(11):1391-6. DOI: 10.1016/j.ijom.2013.05.020.
15. Maschino F, Guillet J, Curien R, Dolivet G, Bravetti P. Oral me-
tastasis: a report of 23 cases. Int J Oral Maxillofac Surg. 
2013;42(2):164-8. DOI: 10.1016/j.ijom.2012.10.029. 
16. Murillo J, Bagan JV, Hens E, Diaz JM, Leopoldo M. Tumors me-
tastasizing to the oral cavity: a study of 16 cases. J Oral Maxil-
lofac Surg. 2013;71(9):1545-51. DOI: 10.1016/j.joms.2013.03.017.
17. Owosho AA, Xu B, Kadempour A, Yom SK, Randazzo J, Ghossein 
RA, et al. Metastatic solid tumors to the jaw and oral soft tis-
sue: A retrospective clinical analysis of 44 patients from a sin-
gle institution. J Craniomaxillofac Surg. 2016;44(8):1047-53. 
DOI: 10.1016/j.jcms.2016.05.013.
18. Lee YH, Lee JI. Metastatic carcinoma of the oral region: An 
analysis of 21 cases. Med Oral Patol Oral Cir Bucal. 
2017;22(3):E359-E65. DOI: 10.4317/medoral.21566.
19. Liu Y, Vargo RJ, Bilodeau EA. Analytic survey of 57 cases of oral 
metastases. J Oral Pathol Med. 2018;47(3):275-80. DOI: 10.1111/
jop.12672. 
20. Rao RS, Patil S, Sanketh D, Amrutha N. Metastatic tumors of 
the oral cavity. J Contemp Dent Pract. 2014;15(2):263-71.
21. Rosario Regalado Rd, Gallana Álvarez S, Creo Martínez T, Herce 
López J, Pereira Gallardo S. Lingual metastasis from renal car-
cinoma. Rev Esp Cir Oral Maxilofac. 2007;29(3):179-81.
22. Santamaria J, Garcia AM, Gil J, Barbier L. Metastasis of a malig-
nant melanoma to the region of an impacted mandibular third 
molar: A case report. J Oral Maxillofac Surg. 1997;55(9):1003-6. 
DOI: 10.1016/s0278-2391(97)90079-3.
23. Ferreras Granado J, García-Rozado González Á, Gómez Oliveira 
G, Vázquez Mahía I, López-Cedrún Cembranos JL. Mandibular 
metastases of gastric adenocarcinoma: A case report. Rev Esp 
Cir Oral Maxilofac. 2007;29(5):319-23.
24. Diaz-Reverand SA, Naval-Gíaz L, Muñoz-Guerra MF, Sastre-
Pérez J, Rodríguez-Campo FJ, Gil-Diez JL. Management of 
medication-related osteonecrosis of the jaw according to 
the clinical grade: An analysis of 19 cases. Rev Esp Cir Oral 
Maxilofac. 2018;40(3) :104-11. DOI:  10.1016/j .maxi-
lo.2017.06.001.
25. Smith J, Birkeland AC, McHugh JB, Spector ME. Maxilla Oste-
onecrosis: a differential diagnosis in patients with metastatic 
cancer on bisphosphonates. J Case Rep Med 2016;5. DOI: 
10.4303/jcrm/235969.
